Physician profile
Argelia Sample
NPI 1003697194
$1,198.86
in general payments reported to CMS, 2019-2025
14 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.98 · 2024: $882 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.68 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $166.45 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $126.97 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $58.00 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $48.41 | 2024 | Invega, Spravato |
| Noven Therapeutics, LLC | $43.77 | 2024-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $38.89 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $28.55 | 2024 | Quviviq |
| Corium, LLC | $21.93 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $21.48 | 2024 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $19.65 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $18.56 | 2025 | Auvelity |
| Exact Sciences Corporation | $18.18 | 2025 | The Cologuard Plus Collection Kit |
| Indivior INC. | $14.34 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Argelia Sample listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.